Dr. Jack Bartram, a consultant pediatric hematologist from Great Ormond Street Hospital for Children in the UK. Dr. Bartram, an expert in improving outcomes for infants with acute lymphoblastic leukemia (ALL), discussed the unique challenges and promising advancements in treating this rare disease.

Key Points from the Interview:

• Infant ALL is a Different Disease: Dr. Bartram emphasized that infant ALL, defined in patients under one year of age, is biologically distinct from ALL in older children. While outcomes for older children have dramatically improved with a cure rate of 90-95%, the outcomes for infants have lagged, with a traditional cure rate of less than 50%.
• Biological Challenges: The poor prognosis for infants is due to the disease’s aggressive biology. A majority of cases are characterized by a gene rearrangement called KMT2A, which is associated with higher risk. Infants also tend to present with a greater burden of disease, a high white blood cell count, and a higher chance of disease in the spinal fluid. The practicalities and toxicities of treating such young children with intensive chemotherapy are also more complex.
• Shifting Treatment Strategies: Understanding the genetic and molecular characteristics of the disease is crucial for risk stratification. The goal is to deliver the right intensity of treatment to avoid both giving too much toxic therapy and giving too little, which could lead to a relapse. In the past, the focus was on intensifying chemotherapy, but this resulted in increased toxicity and treatment-related deaths.
• The Promise of Immunotherapy: The revolutionary shift in treatment has been the introduction of immunotherapy, specifically the drug blinatumomab. This treatment has shown great success in older children and adults and is now being used in infants. Blinatumomab allows for a “de-escalation” of intensive chemotherapy, reducing toxicity and long-term problems while improving the patient’s ability to tolerate treatment.
• A Message of Hope: Dr. Bartram concluded with a hopeful message for families of newly diagnosed infants. He acknowledged the journey is scary, but stressed that things have accelerated in the last two to three years, and there is now real hope and optimism. He highlighted the importance of global collaboration and knowledge-sharing among the international medical community to continue improving outcomes with gentler, more effective therapies.